Skip to content

Efficacy of oral disintegrating strip sildenafil for the treatment of erectile dysfunction: A prospective, Randomized trial

Efficacy of oral disintegrating strip sildenafil for the treatment of erectile dysfunction: A prospective, Randomized trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181121002
Enrollment
120
Registered
2018-11-21
Start date
2018-12-24
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction Erectile dysfunction Men&#39

Interventions

Hart&#45
S (Sildenafil) Dosage form: oral disintegrating strip Dosage: 50 mg/ strip Instruction: participant using 2 strips before having sexual activity which once a week as minimum frequency for 8 weeks dura
Experimental Drug,Active Comparator Drug
strip,tablet

Sponsors

Goverment pharmaceutical organization (GPO)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria • 18 years or older ED patients, defined as erection hardness score (EHS)≤ 3 or International index of erectile function 5 (IIEF-5)≤ 21 • Had a 50% or greater failure rate in maintaining erection long enough to achieve successful intercourse • ED symptoms persist at least 3 months • Patients were required to have been in a monogamous, heterosexual relationship for 3 months or longer and to agree to make at least 2 attempts of intercourse per month. (Patients will receive medication maximum 1 tablet/week or 1 strip/week during crossover period, total 8 tablets, 8 strips/patient)

Exclusion criteria

Exclusion criteria: Exclusion criteria • Patients who have contraindications of PDE5 inhibitors (nitrate use, pre-existing intermediate to high cardiac risk factors) or an allergy or hypersensitivity to a PDE5 inhibitor or a history of consistent treatment failure or dose-limiting AEs during therapy with other PDE5 inhibitors. • ED that resulted from spinal cord injury or radical prostatectomy, blood glucose level greater than 270 mg/dL, and untreated hypogonadism. • Patients who have PSA > 4 ng/dl, clinically significant cardiac, hepatic, or renal disease; orthostatic hypotension; or uncontrolled hypertension or hypotension.

Design outcomes

Primary

MeasureTime frame
Efficacy of oral disintegrating strip sildenafil for the treatment of erectile dysfunction 4 and 8 weeks after initiation of oral disintegrating strip and tablet form EHS and IIEF-5 questionaire

Secondary

MeasureTime frame
time to erection,satisfaction, side effect of oral disintegrating strip sildenafil 4,8 and 12 weeks after initiation of oral disintegrating strip and tablet form questionaire

Countries

Thailand

Contacts

Public ContactPremsant Sangkum

Ramathibodhi hospital, Mahidol Unversity

premsanti@gmail.com0895249204

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026